SUBSCRIBE
SUBSCRIBE

AstraZeneca Pharmaceuticals LP

NEWS
Drug Development
Biopharma Update on the Novel Coronavirus: April 14
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 14, 2020.
April 14, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
BioCapital
Clinical Catch-Up: April 6-10
It was a very busy week for clinical trial news. Here’s a look.
April 10, 2020
 · 
12 min read
 · 
Mark Terry
Courtesy of Alexanderstock23/Shutterstock
Business
AstraZeneca Ramps Up Antibody Research Focused on Treating COVID-19
AstraZeneca made an announcement describing its internal and partnering efforts to battle COVID-19, the disease caused by the novel coronavirus SARS-CoV-2.
April 8, 2020
 · 
3 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: April 8
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 8, 2020.
April 8, 2020
 · 
7 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: April 7
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 7, 2020.
April 7, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
Genetown
In Other (Biopharma) News: Non-Coronavirus Stories this Week
The following is a roundup of some of this week’s non-coronavirus biopharma news.
March 31, 2020
 · 
5 min read
 · 
Alex Keown
Drug Development
AstraZeneca’s Farxiga Shows ‘Overwhelming Efficacy’ in Phase III CKD Trial
AstraZeneca’s Farxiga could be closer to securing approval as a treatment for chronic kidney disease.
March 30, 2020
 · 
2 min read
 · 
Alex Keown
BioCapital
Clinical Catch-Up: March 16-20
Here’s a look at some of last week’s clinical trial news.
March 20, 2020
 · 
7 min read
 · 
Mark Terry
Drug Development
NIH Reports Successful Phase II Results in Pediatric Neurofibromatosis Study
The U.S. National Institutes of Health announced that a Phase II clinical trial of AstraZeneca and Merck’s selumetinib in neurofibromatosis type 1 shrank inoperable tumors.
March 19, 2020
 · 
3 min read
 · 
Mark Terry
Load More
AWARDS
  • 2022 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Press Releases
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification
December 30, 2025
 · 
5 min read
Press Releases
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer
December 23, 2025
 · 
19 min read
Press Releases
DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer
December 23, 2025
 · 
20 min read
Press Releases
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer
December 23, 2025
 · 
19 min read
Press Releases
Niowave Expands Global Supply Agreement with AstraZeneca to Deliver Actinium-225 for Next-Generation Cancer Therapies
December 19, 2025
 · 
2 min read
Press Releases
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy
December 18, 2025
 · 
9 min read
Press Releases
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer
December 16, 2025
 · 
19 min read
Press Releases
ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
December 16, 2025
 · 
19 min read
Press Releases
Roche receives FDA approval for first diagnostic tests to identify HER2-positive metastatic breast cancer patients eligible for ENHERTU
December 16, 2025
 · 
7 min read
Press Releases
DESTINY-Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer
December 10, 2025
 · 
19 min read
Load More